AI Article Synopsis
- OnabotulinumtoxinA (BTX-A) has been recognized for its positive effects on chronic migraine since its initial link 25 years ago and received FDA approval for treatment in 2010.
- The treatment significantly enhances the quality of life for individuals suffering from chronic migraine by offering insights into its neuromodulatory effects and biological mechanisms.
- This Review discusses the breadth of clinical research, including trials and real-world evidence, while also exploring future research directions for BTX-A in migraine management.
Article Abstract
OnabotulinumtoxinA (BTX-A) was first linked to beneficial effects in migraine 25 years ago and was approved by the FDA for preventive treatment of chronic migraine in 2010. The treatment has since had a major impact on the well-being of people with chronic migraine. The clinical development programme for BTX-A and research since its approval have provided insights into the neuromodulatory sensory effect of BTX-A, how it can control chronic migraine despite its peripheral action, and the underlying biology of migraine as a disease. In this Review, we consider the impact that BTX-A has had on the management of chronic migraine and on the research field. We discuss the insights provided by clinical research, encompassing the clinical trials and subsequent real-world evidence, and the mechanistic insights provided by preclinical and translational research. We also provide an overview of future directions of research in the field BTX-A in migraine and the clinical translation of this research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41582-024-01002-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!